Latest Funding News

Celsius Resources has delivered a robust Definitive Feasibility Study for its Maalinao-Caigutan-Biyog Copper-Gold Project, confirming a 35-year mine life and strong economic returns. The company is actively progressing funding arrangements amid growing investor interest.

Nimy Resources has announced a maiden JORC Inferred Resource for high-grade gallium and rare earth elements at its Mons Project in Western Australia, marking a significant step towards becoming a key supplier in critical minerals.

Pilot Energy has made significant strides in Q4 2025 with the launch of a modular data centre joint venture, progress on a hybrid solar and battery project, and advancement of offshore gas exploration partnerships, supported by substantial new financing.

Golden Horse Minerals reports multiple shallow, high-grade gold intersections at Golden Valley and significant deep drilling success at Southern Cross, backed by a $35 million capital raise to fuel 2026 growth.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Cullen Resources Limited has outlined an active exploration agenda for early 2026, advancing drilling programs across its gold and base metal projects in Western Australia and Finland while maintaining a stable financial footing.

Manuka Resources has released an updated 10-year Pre-Feasibility Study for its Cobar Basin projects, revealing a substantial uplift in project economics and a clear path to production by mid-2026.

MRG Metals has expanded its rare earth portfolio through the acquisition of the high-grade Garies Rare Earth Project in South Africa, while also progressing key projects in Mozambique, signalling a diversified growth strategy in critical minerals.

Magmatic Resources has reported encouraging gold assay results from its Weebo Gold Project and advanced drilling at its Myall Copper-Gold JV, alongside securing a $3 million placement led by FMG Resources.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Alpha HPA Limited has successfully raised A$225 million through a fully underwritten equity placement, bolstered by strong institutional support, to fund the next phase of its high purity alumina project. This capital injection, combined with existing cash and government funding, positions the company to advance its Stage 2 construction and expand Stage 1 capacity.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.